Trinayan Kashyap

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

Y-T Tai, Yosef Landesman, Chirag Acharya et al. · Leukemia · 2013 · 299 citations · Full text

Tumor Biology, Oncology, Bone Morphogenic Protein +10

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

Ramiro Garzon, Michael R. Savona, Rachid Baz et al. · Blood · 2017 · 147 citations · Full text

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death

Trinayan Kashyap, Christian Argueta, Amro Aboukameel et al. · Oncotarget · 2016 · 125 citations · Full text

Proteasome Inhibitors, Chemoprevention Strategy, Immunology +20

XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus

Parvathi Ranganathan, Trinayan Kashyap, Xueyan Yu et al. · Clinical Cancer Research · 2016 · 93 citations · Full text

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

Joel G. Turner, Trinayan Kashyap, Jana L. Dawson et al. · Oncotarget · 2016 · 88 citations · Full text

Hematological Malignancy, Tumor Biology, Proteasome Inhibitor Resistance +13